| ISSN |
2220-3141(online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Critical Care Medicine |
| Manuscript Type |
Observational Study |
| Article Title |
Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jose I Iglesias, Andrew V Vassallo, Jesse B Sullivan, Yasmine Elbaga, Vishal V Patel, Nikunjkumar Patel, Lydia Ayad, Payam Benson, Marina Pittiglio, Emad Gobran, Alexander Clark, Wajahat Khan, Kaliope Damalas, Rajesh Mohan and Satyendra P Singh |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jose I Iglesias, Consultant, Associate Professor, Department of Critical Care, Community Medical Center, 99 W Rt 37, Toms River, NJ 08757, United States. jiglesias23@gmail.com |
| Key Words |
COVID-19; Corticosteroids; Intensive care unit; Methylprednisolone; Tociluzimab; Anti-inflammatory |
| Core Tip |
Anti-inflammatory therapy with glucocorticoids (including methylpredsnisolone) and combination treatment with tocilizumab and glucocorticoids improve survival in critically ill patients with coronavirus disease 2019. Dual inhibition of the NFK-β therapy with glucocorticoid and inhibition of the interleukin-6 pathway with tocilizumab may offer greater survival benefits. |
| Publish Date |
2021-09-09 09:23 |
| Citation |
Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y, Patel VV, Patel N, Ayad L, Benson P, Pittiglio M, Gobran E, Clark A, Khan W, Damalas K, Mohan R, Singh SP. Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. World J Crit Care Med 2021; 10(5): 244-259 |
| URL |
https://www.wjgnet.com/2220-3141/full/v10/i5/244.htm |
| DOI |
https://dx.doi.org/10.5492/wjccm.v10.i5.244 |
